Artivion, Inc. (NYSE:AORT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Artivion, Inc. (NYSE:AORT) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $46.1667.

A number of brokerages have recently weighed in on AORT. Needham & Company LLC cut their price target on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. Citizens Jmp cut their price target on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Canaccord Genuity Group cut their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a report on Friday, April 10th. Finally, Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th.

Artivion Stock Performance

Shares of Artivion stock opened at $20.48 on Thursday. The company has a 50 day moving average of $29.52 and a 200-day moving average of $37.33. Artivion has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The company has a market cap of $994.29 million, a PE ratio of 85.35 and a beta of 1.26.

Hedge Funds Weigh In On Artivion

Several institutional investors and hedge funds have recently added to or reduced their stakes in AORT. Conestoga Capital Advisors LLC bought a new position in Artivion in the 1st quarter valued at approximately $43,044,000. Summit Partners Public Asset Management LLC bought a new position in Artivion in the 4th quarter valued at approximately $39,401,000. Invesco Ltd. lifted its stake in Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after purchasing an additional 748,119 shares during the last quarter. Champlain Investment Partners LLC bought a new position in Artivion in the 3rd quarter valued at approximately $17,912,000. Finally, Goldman Sachs Group Inc. lifted its stake in Artivion by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock valued at $24,510,000 after purchasing an additional 317,518 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.